WO2013165159A1 - Composition for accelerating regeneration after laser surgery - Google Patents

Composition for accelerating regeneration after laser surgery Download PDF

Info

Publication number
WO2013165159A1
WO2013165159A1 PCT/KR2013/003744 KR2013003744W WO2013165159A1 WO 2013165159 A1 WO2013165159 A1 WO 2013165159A1 KR 2013003744 W KR2013003744 W KR 2013003744W WO 2013165159 A1 WO2013165159 A1 WO 2013165159A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
laser treatment
skin
collagen
skin regeneration
Prior art date
Application number
PCT/KR2013/003744
Other languages
French (fr)
Korean (ko)
Inventor
김병규
김정기
신현정
서대방
이상준
이지해
배일홍
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020130047359A external-priority patent/KR102064469B1/en
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2013165159A1 publication Critical patent/WO2013165159A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to a composition for promoting skin regeneration after a laser treatment comprising a collagen peptide, and more particularly to a composition for promoting skin regeneration after a laser treatment comprising a collagen tripeptide.
  • Skin regeneration is a process of tissue repair that involves chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, angiogenesis, and reconstruction of wounds. Complex biological processes have been reported (Steed, DL et al., Clin. Plast. Surg. 25, 397, 1998).
  • Skin regeneration involves several processes, including inflammation, re-epithelial izat ion, granulation of granulation tissue, fibroplasia, and contraction of wound tissue. (Freedberg et al., 2001). In this process of skin regeneration, keratinocytes and fibroblasts of skin tissue play an important role, and collagen synthesis through the activation of fibroblasts is particularly important.
  • the present inventors confirmed in vitro that the collagen peptide activates skin cells and promotes the movement of cells, and after laser treatment by ex vivo and animal experiments using artificial skin. Skin regeneration or laser treatment After confirming that it can be helpful for after-care and completed the present invention ⁇
  • An object of the present invention is to provide a composition for promoting skin regeneration after laser treatment, specifically, a composition for after care after laser treatment.
  • the present invention provides a composition for promoting skin regeneration after laser treatment comprising a collagen peptide as an active ingredient, wherein the collagen peptide comprises 15% by weight or more of the collagen peptide in the total collagen peptide , Provide a composition for promoting skin regeneration after laser treatment.
  • composition according to the present invention activates skin cells (keratinocytes, fibroblasts), increases the movement of cells, and in particular, can promote the regeneration of the skin after laser treatment, so that the recovery of the skin after laser treatment It is useful for increasing skin elasticity, minimizing skin moisture loss, and improving erythema.
  • FIG. 1 is a graph showing the increase in cellular activity of dermal fibroblasts (NHDF), keratinocytes (HaCaT) as the 1, 10, 100 / g / in ⁇ collagen peptide, respectively.
  • FIG. 2 is a diagram showing that the cell migration of keratinocytes increases as the 3, 30 ⁇ g / v ⁇ i collagen peptides are respectively treated.
  • FIG. 3 is a diagram showing that recovery of skin tissue is promoted after laser treatment in artificial skin as the 10, 100 ⁇ g / ml collagen peptides are treated, respectively.
  • 4 is a graph showing that the recovery of the skin is accelerated by administering 600 mpk / day collagen peptide to mice.
  • 5 to 8 are graphs showing that the items of skin elasticity, moisturizing, enjoyment, and patient satisfaction, which have been degraded due to the laser, are improved as the human ingests 1 g / day collagen peptide, respectively.
  • Figure 9 shows the amount of hard epidermal moisture loss by applying lmg / ml collagen peptide to the skin
  • TEWL is a graph showing reduced moisturizing benefits.
  • Figure 10 is a graph showing that the recovery of the Heungban index is fast as taking oral low molecular collagen peptide for 4 weeks.
  • FIG. 11 is a graph showing the change in the pigment index according to taking oral low molecular collagen peptide for 4 weeks.
  • Figure 12 is a graph that extent, light skin water loss (TEWU as taking a low molecular weight collagen peptide for 4 weeks oral administration is to be returned to normal showing a more rapid "than the control group,
  • Figure 13 is a graph showing that the recovery of the skin moisture (Corneometer) is faster than the control group by taking oral low molecular collagen peptide for 4 weeks.
  • FIG. 14 is a graph showing a subjective satisfaction evaluation result of patients taking oral low molecular weight collagen temperate for 4 weeks.
  • the present invention provides a composition for promoting skin regeneration after a laser treatment comprising a collagen peptide as an active ingredient, wherein the collagen peptide comprises a collagen tripeptide containing 15 weight 3 ⁇ 4 or more of the total collagen peptides. It relates to a composition for promoting skin regeneration after the procedure.
  • Collagen is one of the light proteins and contains a small amount of sugars. It is a major component of connective tissue substrates and in mammals comprises about 30% by weight of total protein. Dermis of the animal-tendon is present in fibrous form and gathered into collagen fibers. The basic unit constituting the fiber is tropocollagen with a molecular weight of about 300,000 280 nm long and 1.5 nm thick.
  • the collagen peptide used as an active ingredient in the present invention is gelatin (HATC,
  • the amino acids include glycine, alanine valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, phenylalanine, tyrosine, tryptophan or proline.
  • a peptide purified with a high content of tripeptiform in the form of Gly-XY can be prepared by the following method.
  • Collagen or gelatin components are digested with enzymes such as cysteine protease, pepsin, trypsin or collagenase to prepare collagen peptides containing at least 5 3 ⁇ 4> dipeptide and dipeptide.
  • the peptide mixture containing the Gly-XY-type peptide was contacted with an alkaline negative exchange resin, After adsorbing tripeptide Gly-XY on the ion exchange resin, the peptide is eluted from the ion exchange resin adsorbed on the tripeptide to prepare a peptide purified with a higher content of tripeptide.
  • a hydrophilic tree by contacting a peptide mixture containing tripeptide Gly-XY with a nonpolar adsorbent, adsorbing a portion of the hydrophobic peptide contained in the peptide mixture to the nonpolar adsorbent, and recovering the hydrophilic tripeptide that does not adhere to the nonpolar adsorbent Peptide purified products with high content of peptides can be prepared.
  • 'collagen tripeptide' is a peptide constituting collagen, and means a structure including three specific peptides.
  • the 'laser procedure' refers to the act of irradiating the laser to the skin.
  • the area of skin to be irradiated is not limited throughout the body, and specifically includes the face and the neck.
  • Laser surgery refers to the acts performed for cosmetic or medical purposes. Specifically, laser treatment is performed to remove spots, blemishes, and spots, or laser treatment is performed to alleviate acne traces, to whiten skin, to promote regeneration, or to reduce fungus.
  • deep L or intended to include the case of removing hageo treatment laser to mitigate or a discolored scar, the scar, but may be obtained by an image or a traffic accident to obtain the volume, will be limited to "is not.
  • 'regenerating' the skin induces or promotes the activity of the fiber cells in the laser-treated skin or moves the fiber cells to the laser-treated skin area, thereby regenerating the skin or promoting recovery. Or to promote the production of new skin.
  • composition of the present invention can enhance the elasticity of the skin which has been degraded by the laser, promote the activity and movement of skin cells, improve the skin uplift, recovery of the skin, specifically laser treatment It can be usefully used for aftercare of skin after.
  • the collagen tripeptide is Gly-X-Y.
  • the collagen tripeptide may have three peptide structures that include glycine (Glycine, Gly), and there is no limitation on the type of amino acid that may come in the X or Y position.
  • the amino acid is glycine, Alanine, valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, phenylalanine, thi Leucine, tryptophan or proline.
  • X may be proline.
  • Y may be hydroxyproline.
  • the collagen tripeptide may be a tripeptide sequence of Gly-Pn) -Hyp.
  • the tripeptides of Gly-Pro-Hyp may be 2.4 to 3.6% by weight of the total collagen tripeptides.
  • the tripeptides of Gly-Pro—Hyp may be about 3% by weight of the total collagen tripeptides.
  • the composition for promoting skin regeneration after the laser treatment may include collagen tripeptide in an amount of 15 wt% or more to 90 wt% or less of the total collagen peptide. If the collagen tripeptide is included at less than 15 weight 3 ⁇ 4, the healing of the wound proceeds slowly, and if the collagen tripeptide is included at more than 90 wt% &, the content of other components is reduced.
  • the composition for wound repair may comprise at least 20 wt% to 85 wt%, at least 25 wt% to 80 wt% or less, at least 30 wt% to 75 wt%, of the collagen tripeptide in the total collagen peptide, 35 Or more than 70% by weight or less than 40% by weight or more and 65% by weight or less.
  • the collagen peptide may be contained in an amount of 1 to 80 wt% based on the total weight of the composition. If the content of the collagen peptide is less than 1% by weight, it is difficult to obtain the desired effect, and if it exceeds 80% by weight, it is difficult to formulate.
  • the collagen peptide of the present invention is characterized by 1-80 weight%, 3-78 weight%, 5-76 weight 3 ⁇ 4, 7-74 weight 3 ⁇ 4, 9-72 weight%, 11-70 weight%, 13-68 weight%, 15-66 weight 17-64 weight % Or 19 to 62 weight 3 ⁇ 4.
  • the composition may be for promoting the movement of skin fiber cells.
  • the fibrous cells may include keratinocytes or fibroblasts, but are not limited thereto.
  • the composition may move the skin fiber cells or further promote the movement of the fiber cells.
  • the composition may be for promoting the activity of skin fibroblasts.
  • the fibrous cells may include keratinocytes or fibroblasts, but are not limited thereto.
  • the composition may activate skin fibroblasts or further promote the activity of fibroblasts.
  • the composition may be for increasing skin elasticity.
  • the composition can improve the elasticity of the skin to create a sagging skin, to minimize the moisture loss of the skin, it can be adjusted to the oil and moisture balance.
  • the composition is for reducing skin plaque Can be.
  • the composition can reduce the redness of the skin due to external irritation caused by the laser.
  • the composition may further include vitamin C. Including more vitamin C can further increase the activity of fibroblasts and keratinocytes.
  • the composition may be a pharmaceutical composition.
  • the composition according to the present invention When the composition according to the present invention is applied to a pharmaceutical product, the composition may be formulated as an oral or parenteral dosage form in solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier. Can be.
  • preparations for oral administration include tablets, pills, granules, capsulants, powders, fine granules, powders, emulsions, syrups, pellets, and the like.
  • preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like.
  • active ingredient of the present invention it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, loosening agents, suspending agents, and other commercially available auxiliaries can be suitably used.
  • compositions according to the invention may be administered by oral, parenteral, rectal i topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous and the like.
  • the dosage of the active ingredient will vary depending on the age, sex, weight of the subject to be treated and the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day.
  • the oral dosage of collagen peptide may be at least 0.005 g / kg / day, may be at least 0.01 g / kg / day, may be at least 0.02 g / kg / day. In one embodiment of the present invention, the oral dosage of collagen peptide may be 0.5 g / kg / day or less, 0.2 g / kg / day or less, and 0.1 g / kg / day or less.
  • the composition may be a health food composition.
  • the composition according to the present invention provides various types of food additives or functional foods. Fermented milk cheese, yogurt, juice, probiotic, tablets, granules, drinks, caramel, diet bar, etc. containing the composition may be formulated, It can be processed into the form of tea leaves or tea bags and health supplements, and can be used in the form of various other food additives.
  • the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickener inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickener inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • auxiliary ingredients such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract.
  • the components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention.
  • the added amount of the components may range from 0.01-5% by weight, more specifically 0.01-3% by weight, based on the total weight of the composition.
  • Formulations of the compositions according to the invention may be in various forms, such as solutions, emulsions, viscous mixtures, tablets, powders, which are administered by a variety of methods, such as simple drinking, injection spray or squeeze. Can be.
  • the composition may be a cosmetic composition.
  • the cosmetic composition according to the present invention may be provided in any formulation suitable for topical application.
  • it can be provided in the form of emulsions obtained by dispersing the oil phase in solution, water phase, emulsions obtained by dispersing the water phase in oil phase, suspensions, solids, gels, powders, pastes, foams or aerosol compositions. have.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range of not impairing the main effect, preferably other synergistic effects.
  • the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, an ultraviolet absorbent, a preservative, a fungicide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent or a limiting agent.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0.01 to 5% by weight, specifically 0,01 to 3% by weight based on the total weight of the composition May be 3 ⁇ 4.
  • the collagen peptide used as an active ingredient in the present invention is a gel rice company (HATC,
  • Fibroblasts (NHDF) (Korea Cell Line Bank, CCD986sk, KCLB, Korea) and keratinocytes (HaCaT) (Dr N.E. Fusenig.Deutsches Krebsforschungstechnik,
  • PBS was treated with 1/1000 of the media volume.
  • MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-dihenyl tetrazolium bromide dissolved in physiological saline; Sigma, USA] 300 ⁇ each solution was added to each well and incubated for 4 hours. After incubation, the medium was removed and the formazan crystals formed by the addition of 200 ⁇ dimethyl sulfoxide (DMS0; Junsei, Japan) were dissolved, and then transferred onto 96-well folate, followed by ELISA analyzer (Spectra MAX 250, Molecular Devices Co., USA) and absorbance at 540 nm. Each experiment was repeated three times. The experimental results are shown in FIG. Referring to FIG. 1, collagen peptides were found to promote cell activity in a concentration-dependent manner, and furthermore, cell collagen peptides and vitamin C were simultaneously treated to increase cell activity.
  • keratinocytes were seeded in 6 well plates at a density of 2 ⁇ 10 5 cells / well. The next day, the collagen peptide of Example 1 was treated with 3, 30 iigl ⁇ , concentration. After 12 hours confluent cells were scratched with a fine pipette tip and washed with PBS. 0, 46 hours after the political culture was photographed. Cell migration was observed by photographing under a microscope (X 50). The experimental results are shown in FIG. 2, referring to FIG. 2, it can be seen that the collagen peptide promotes cell migration in a concentration-dependent manner.
  • hairless mice were selected as an animal model and tested. 6-7 week old female hairless mice (hair less mouse, SKH, HR-1) as a control group, as shown in Table 2 was divided into 10 animals per group in the experimental period was raised during the experiment.
  • Example 2 collagen peptide was administered orally using a syringe for liquid administration by mixing 600 mg of powder per weight (kg) in 0.5 ml saline based on solid content. It was. The administration period was 4 weeks in total at the same time. Wounds were formed using punches on the back of mice two weeks after oral administration. Thereafter, the area of the wound produced during the two weeks was measured to observe the tendency of the area to decrease. The experimental results are shown in FIG. 4. Referring to Figure 4, it can be seen that collagen peptides promote the recovery of wounds.
  • the experiment was carried out by dividing 20 healthy adult women without a history of atopic dermatitis or allergic diseases into two groups.
  • the experimental group applied lmg / ml collagen peptide dissolved in water to the skin, and the control group applied water to the skin. After 3 hours of application, the water loss (TEWL) of the skin was accumulated (FIG. 9).
  • Laser treatment was performed using a non-invasive 1550nm, Fraxel laser (Sellas, Dinona, Seoul, Korea) with a stamp mode of 13 mJ / microthermal treatment zone.
  • the erythema index was significantly increased immediately after the treatment in both the control and experimental groups, and returned to normal after 1 week.
  • the melanin index was slightly decreased immediately after the treatment in both the control and experimental groups, but returned to the baseline after 3 days. It is thought that the pigment index was relatively low as the erythema index increased immediately after the procedure. There was no statistically significant difference between the control group and the experimental group, and the experimental results are shown in FIG. 11.
  • TEWL Hard epidermal moisture loss
  • ⁇ 90> 150 mg of collagen peptide of Preparation Example 1 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C. Formed and stratified to the fabric. The final weight of the content was 1 g.
  • composition ratio of the above-mentioned vitamin and mineral mixtures is a composition which is relatively suitable for health foods in a preferred embodiment, but the composition ratio may be arbitrarily modified.
  • the granules can then be prepared and used to prepare health food compositions according to conventional methods.
  • the resulting solution was filtered, taken in a sterile 2 £ container, sealed, sterilized and stored at room temperature before use in the manufacture of a healthy beverage composition of the present invention.
  • composition ratio is a relatively preferred component suitable for a favorite beverage in a preferred embodiment Although it is established, the proportion may be arbitrarily modified according to regional and ethnic preferences such as demand class, demand country, and use purpose. Those of ordinary skill in the art to which the present invention pertains will be able to perform various uses and modifications within the scope of the present invention based on the above contents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a composition for accelerating skin regeneration after laser surgery, containing a collagen peptide, and more specifically, to a composition for accelerating skin regeneration after laser surgery, containing a collagen tripeptide.

Description

【명세서】  【Specification】
【발명의 명칭】  [Name of invention]
레이저 시술 후 재생 촉진용 조성물  Composition for promoting regeneration after laser treatment
【기술분야】  Technical Field
<1> 본 발명은 콜라겐 펩타이드를 포함하는 레이저 시술 후 피부의 재생 촉진용 조성물에 관한 것으로， 구체적으로 콜라겐 트리펩타이드를 포함하는, 레이저 시술 후 피부의 재생 촉진용 조성물에 관한 것이다.  The present invention relates to a composition for promoting skin regeneration after a laser treatment comprising a collagen peptide, and more particularly to a composition for promoting skin regeneration after a laser treatment comprising a collagen tripeptide.
【배경기술】  Background Art
<2> 피부의 재생은 조직 회복의 과정으로 주화성 (chemotaxis), 세포의 분화 및 복제 (differentiation and replication), 기질 단백질 (matrix protein)의 합성, 혈 관의 신생， 창상의 재구성 등을 포함하는 복잡한 생물학적 과정으로 보고되어져 있 다 (Steed, D.L. et al . , Clin.Plast. Surg. 25， 397, 1998) .  <2> Skin regeneration is a process of tissue repair that involves chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, angiogenesis, and reconstruction of wounds. Complex biological processes have been reported (Steed, DL et al., Clin. Plast. Surg. 25, 397, 1998).
<3> 피부의 재생은 면역반웅 (inflammation), 재상피화 (reepithel ial izat ion)， 육 아조직의 형성 (granulation), 섬유조직형성 (fibroplasia)， 상처조직의 수축 (contraction) 등 여러 가지 과정을 통해 이루어진다 (Freedberg et al . , 2001). 이 러한 피부 재생의 과정에서 피부조직의 각질세포 (keratinocytes)와 섬유아세포 (fibroblasts) 둥이 중요한 역할을 하며， 특히 섬유아세포의 활성화를 통한 콜라겐 합성이 매우 중요하다.  <3> Skin regeneration involves several processes, including inflammation, re-epithelial izat ion, granulation of granulation tissue, fibroplasia, and contraction of wound tissue. (Freedberg et al., 2001). In this process of skin regeneration, keratinocytes and fibroblasts of skin tissue play an important role, and collagen synthesis through the activation of fibroblasts is particularly important.
<4> 최근 레이저를 이용한 의료 행위가 광범위하게 확대되고 있다. 구체적으로 <4> In recent years, medical activities using lasers have been widely expanded. Specifically
BCC 리서치가 최근 발간한 보고서에 의하면 2009년 세계시장은 약 23억 달러의 규 모를 기톡하였고, 앞으로 5년간은 연평균성장률 (CAGR)이 16.1%으로 기대되며, 2014 년에는 48억 달러 규모에 도달할 것으로 예측된다고 한다. 피부과에서 행해지는 의 료용 레이저 시술은 피부의 여러 가지 병변을 치료하는데 매우 효율적이나， 레이저 를 이용한 치료는 기본적으로 정상피부를 천공함으로써 일반적인 피부를 구성하는 세포들을 파괴시키고， 파괴된 세포들로 인해 비세균성 염증반응을 유발하게 되어， 출혈, 통증， 부종， 홍조 등의 증상이 시술을 받는 환자들에게 고통과 블편함을 증 대시킨다. 또한， 염증반웅이 길어지게 되면 감염， 및 염증 후 색소침착 등의 부작 용을 증가시킨다는 문제점이 있다. 따라서， 레이저 시술 후 회복기를 줄여줄 수 있 는 방법들이 요구되고 있다. According to a recent report published by BCC Research, the global market in 2009 was worth about $ 2.3 billion, with an average annual growth rate (CAGR) of 16.1% over the next five years, reaching $ 4.8 billion in 2014. It is said to be expected. Medical laser procedures performed in dermatology are very effective in treating various lesions of the skin, but laser-based treatment basically destroys the cells that make up the general skin by puncturing normal skin. It causes inflammatory reactions, and symptoms such as bleeding, pain, edema, and flushing increase the pain and discomfort in the patients undergoing the procedure. In addition, when the inflammation response is prolonged, there is a problem of increasing side effects such as infection and pigmentation after inflammation. Therefore, there is a need for a method for reducing the recovery period after laser treatment.
<5> 이에 본 발명자들은 콜라겐 펩타이드가 피부 세포를 활성화시키며， 세포의 이동을 촉진시키는 것을 시험관 내 (in vitro)에서 확인하였고， 인공피부를 이용한 탈체실험 (ex vivo) 및 동물실험으로 레이저 시술 후 피부의 재생ᅳ 즉 레이저 시술 후 애프터 케어를 위하여 도움이 될 수 있음이 확인하고 본 발명올 완성하게 되었 다ᅳ The present inventors confirmed in vitro that the collagen peptide activates skin cells and promotes the movement of cells, and after laser treatment by ex vivo and animal experiments using artificial skin. Skin regeneration or laser treatment After confirming that it can be helpful for after-care and completed the present invention ᅳ
【발명의 상세한 설명】  [Detailed Description of the Invention]
【기술적 과제】  [Technical problem]
<6> 본 발명의 목적은 레이저 시술 후 피부의 재생 촉진용 조성물， 구체적으로， 레이저 시술 후 애프터 케어용 조성물을 제공하는 데 있다.  An object of the present invention is to provide a composition for promoting skin regeneration after laser treatment, specifically, a composition for after care after laser treatment.
<7> 본 발명의 목적은 지금까지 보고된 바가 없는, 경구용 제제를 이용한 레이저 시술 후 피부의 재생 촉진용 조성물을 제공하는 데 있다.  It is an object of the present invention to provide a composition for promoting skin regeneration after laser treatment using an oral preparation, which has not been reported so far.
ί기술적 해결방법】  ί Technical Solution
<8> 상기 목적을 달성하기 위하여， 본 발명은 콜라겐 펩타이드를 유효성분으로 포함하는 레이저 시술 후 피부의 재생 촉진용 조성물로서， 상기 콜라겐 펩타이드는 콜라겐 트리펩타이드를 전체 콜라겐 펩타이드 중 15 중량 % 이상 포함하는， 레이저 시술 후 피부의 재생 촉진용 조성물을 제공한다.  In order to achieve the above object, the present invention provides a composition for promoting skin regeneration after laser treatment comprising a collagen peptide as an active ingredient, wherein the collagen peptide comprises 15% by weight or more of the collagen peptide in the total collagen peptide ， Provide a composition for promoting skin regeneration after laser treatment.
【유리한 효과】  Advantageous Effects
<9> 본 발명에 의한 조성물은 피부세포 (각질세포, 섬유아세포)를 활성화시키고， 세포의 이동을 증가시키며, 특히， 레이저 시술 후 피부의 재생을 촉진할 수 있어 서, 레이저 시술 후 피부의 회복을 촉진할 뿐 아니라， 피부 탄력을 증가시키고, 피 부의 수분 손실을 최소화하며 , 홍반을 개선할 수 있어서 유용하다。  The composition according to the present invention activates skin cells (keratinocytes, fibroblasts), increases the movement of cells, and in particular, can promote the regeneration of the skin after laser treatment, so that the recovery of the skin after laser treatment It is useful for increasing skin elasticity, minimizing skin moisture loss, and improving erythema.
【도면의 간단한 설명】  [Brief Description of Drawings]
<ιο> 도 1은 1, 10, 100 /g/in^ 콜라겐 펩타이드를 각각 처리함에 따라， 피부섬유 아세포 (NHDF), 각질세포 (HaCaT)의 세포활성이 증가하는 것을 나타낸 그래프이다. <π> 도 2는 3， 30 βg/v^i 콜라겐 펩타이드를 각각 처리함에 따라， 각질세포의 세 포이동이 증가하는 것을 나타낸 그림이다.  <ιο> Figure 1 is a graph showing the increase in cellular activity of dermal fibroblasts (NHDF), keratinocytes (HaCaT) as the 1, 10, 100 / g / in ^ collagen peptide, respectively. <π> FIG. 2 is a diagram showing that the cell migration of keratinocytes increases as the 3, 30 βg / v ^ i collagen peptides are respectively treated.
<12> 도 3은 10， 100 βg/ml 콜라겐 펩타이드를 각각 처리함에 따라, 인공피부에서 레이저로 시술 후 피부 조직의 회복이 촉진되는 것을 나타낸 그림이다. FIG. 3 is a diagram showing that recovery of skin tissue is promoted after laser treatment in artificial skin as the 10, 100 βg / ml collagen peptides are treated, respectively.
<13> 도 4는 600 mpk/day 콜라겐 펩타이드를 생쥐에게 투여함에 따라, 피부의 회 복이 촉진되는 것을 나타낸 그래프이다. 4 is a graph showing that the recovery of the skin is accelerated by administering 600 mpk / day collagen peptide to mice.
<14> 도 5 내지 도 8은 각각 1 g/day콜라겐 펩타이드를 사람이 섭취함에 따라, 레 이저로 인해 저하되었던 피부의 탄력, 보습， 흥반， 환자의 만족도의 항목들이 개선 되는 것을 나타낸 그래프이다. 5 to 8 are graphs showing that the items of skin elasticity, moisturizing, enjoyment, and patient satisfaction, which have been degraded due to the laser, are improved as the human ingests 1 g / day collagen peptide, respectively.
<15> 도 9은 lmg/ml 콜라겐 펩타이드를 피부에 도포함에 따라， 경표피수분손실량 Figure 9 shows the amount of hard epidermal moisture loss by applying lmg / ml collagen peptide to the skin
(TEWL)이 감소하여 보습에 도움이 되는 것을 나타낸 그래프이다. <16> 도 10은 4주간 경구용 저분자 콜라겐 펩타이드를 복용함에 따라， 흥반지수의 회복이 빠른 것을 나타낸 그래프이다. (TEWL) is a graph showing reduced moisturizing benefits. Figure 10 is a graph showing that the recovery of the Heungban index is fast as taking oral low molecular collagen peptide for 4 weeks.
<17> 도 11은 4주간 경구용 저분자 콜라겐 펩타이드를 복용함에 따른 색소지수의 변화를 나타낸 그래프이다. FIG. 11 is a graph showing the change in the pigment index according to taking oral low molecular collagen peptide for 4 weeks.
<18> 도 12는 4주간 경구용 저분자 콜라겐 펩타이드를 복용함에 따라， 경표피수분 손실량 (TEWU이 정상으로 회복되는 정도가 대조군에 비해 더 빠른'것을 나타낸 그 래프이다, <18> Figure 12 is a graph that extent, light skin water loss (TEWU as taking a low molecular weight collagen peptide for 4 weeks oral administration is to be returned to normal showing a more rapid "than the control group,
<19> 도 13은 4주간 경구용 저분자 콜라겐 펩타이드를 복용함에 따라， 피부 수분 도 (Corneometer)의 회복이 대조군에 비해 더 빠른 것을 나타낸 그래프이다.  Figure 13 is a graph showing that the recovery of the skin moisture (Corneometer) is faster than the control group by taking oral low molecular collagen peptide for 4 weeks.
<20> 도 14은 4주간 경구용 저분자콜라겐 템타이드를 복용함에 따른 환자의 주관 적인 만족도 평가결과를 나타낸 그래프이다.  FIG. 14 is a graph showing a subjective satisfaction evaluation result of patients taking oral low molecular weight collagen temperate for 4 weeks.
【발명의 실시를 위한 최선의 형태】  Best Mode for Implementation of the Invention
<21> 본 발명은 일 관점에서， 콜라겐 펩타이드를 유효성분으로 포함하는 레이저 시술 후 피부의 재생 촉진용 조성물로서, 상기 콜라겐 펩타이드는 콜라겐 트리펩타 이드를 전체 콜라겐 펩타이드 중 15 중량 ¾ 이상 포함하는， 레이저 시술 후 피부의 재생 촉진용 조성물에 관한 것이다.  In one aspect, the present invention provides a composition for promoting skin regeneration after a laser treatment comprising a collagen peptide as an active ingredient, wherein the collagen peptide comprises a collagen tripeptide containing 15 weight ¾ or more of the total collagen peptides. It relates to a composition for promoting skin regeneration after the procedure.
<22> 콜라겐은 경단백질의 하나이고 소량의 당을 함유한다. 결합조직 기질의 주성 분이고 포유동물의 경우 총 단백질의 약 30 중량 %를 차지한다. 동물의 진피 .건 - 연골 등에 섬유상으로 존재하고 모여서 교원섬유가 된다. 섬유를 구성하는 기본단 위는 분자량 약 30만 길이 280nm, 굵기 1.5nm의 트로포콜라겐이다,  Collagen is one of the light proteins and contains a small amount of sugars. It is a major component of connective tissue substrates and in mammals comprises about 30% by weight of total protein. Dermis of the animal-tendon is present in fibrous form and gathered into collagen fibers. The basic unit constituting the fiber is tropocollagen with a molecular weight of about 300,000 280 nm long and 1.5 nm thick.
<23> 본 발명에서 활성성분으로 사용되는 콜라겐 펩티드는 젤라이스사 (HATC,  <23> The collagen peptide used as an active ingredient in the present invention is gelatin (HATC,
Jellice Co., JAPAN)에서 제공한 Gly— X-Y 형태의 트리펩타이드 (tripeptide)를 15 중량 % 이상 함유한 복합물로서， 이때 X 또는 Y는 어떠한 아미노산도 가능하다. 구 체적으로， 상기 아미노산은 글라이신， 알라닌 발린， 류신, 이소류신， 트레오닌, 세린, 시스테인, 메티오닌, 아스파르트산, 아스파라긴, 글루탐산, 글루타민， 리신， 아르기닌, 히스티딘, 페닐알라닌, 티로신, 트립토판 또는 프롤린을 포함한다.  Jellice Co., JAPAN), which contains at least 15% by weight of Gly—X-Y-type tripeptide, wherein X or Y may be any amino acid. Specifically, the amino acids include glycine, alanine valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, phenylalanine, tyrosine, tryptophan or proline.
<24> 추가적으로， 다음과 같은 방법으로 Gly-X-Y 형태의 트리펩타이드의 함량이 높은 펩티드 정제물을 제조할 수 있다. 콜라겐 또는 젤라틴 성분을 시스테인프로테 아제， 펩신， 트립신 또는 콜라게나아제 등의 효소로 분해시켜서 ¾리펩타이드 및 디펩타이드를 5 중량 ¾> 이상 함유한 콜라겐 펩타이드를 제조한다. 상기 제조한 펩타 이드 흔합물에서 트리펩타이드의 함량을 보다 높이기 위해서는 Gly-X-Y 형태의 트 리펩타이드를 함유한 펩티드 흔합물을 알칼리성 음이은 교환 수지와 접촉시키고， 트리펩타이드 Gly-X-Y를 상기 이온 교환 수지에 흡착시킨 다음， 트리펩타이드를 흡 착한 이온 교환 수지로부터 트리펩타이드를 용출하면， 트리펩타이드의 함량이 보다 높은 펩티드 정제물을 제조한다. 트리펩타이드 Gly-X-Y를 함유한 펩타이드 흔합물 을 비극성 흡착제와 접촉시켜， 펩타이드 혼합물에 함유된 소수성 펩타이드의 일부 를 비극성 흡착제에 흡착시키고, 비극성 흡착제에 홉착하지 않은 친수성 트리펩타 이드를 회수함으로써， 친수성 트리펩타이드의 함량이 높은 펩티드 정제물을 제조할 수 있다. In addition, a peptide purified with a high content of tripeptiform in the form of Gly-XY can be prepared by the following method. Collagen or gelatin components are digested with enzymes such as cysteine protease, pepsin, trypsin or collagenase to prepare collagen peptides containing at least 5 ¾> dipeptide and dipeptide. In order to increase the content of the tripeptide in the prepared peptide complex, the peptide mixture containing the Gly-XY-type peptide was contacted with an alkaline negative exchange resin, After adsorbing tripeptide Gly-XY on the ion exchange resin, the peptide is eluted from the ion exchange resin adsorbed on the tripeptide to prepare a peptide purified with a higher content of tripeptide. A hydrophilic tree by contacting a peptide mixture containing tripeptide Gly-XY with a nonpolar adsorbent, adsorbing a portion of the hydrophobic peptide contained in the peptide mixture to the nonpolar adsorbent, and recovering the hydrophilic tripeptide that does not adhere to the nonpolar adsorbent Peptide purified products with high content of peptides can be prepared.
<25> 본 명세서에서 '콜라겐 트리펩타이드 '는 콜라겐을 구성하는 펩타이드로서， 특정한 3개의 펩타이드를 포함하는 구조를 의미하는 것이다.  In the present specification, 'collagen tripeptide' is a peptide constituting collagen, and means a structure including three specific peptides.
<26> 본 명세서에서 '레이저 시술 '은 레이저를 피부에 조사하는 행위를 의미한다.  In the present specification, the 'laser procedure' refers to the act of irradiating the laser to the skin.
조사되는 피부 부위는 신체 전 부위에 걸쳐서 제한이 없으며， 구체적으로， 얼굴， 목 둥을 포함한다. 레이저 시술은 미용 또는 의료의 목적으로 이루어지는 행위를 의미하는 것이다. 구체적으로, 점， 기미, 반점 둥의 제거를 위하여 레이저를 시술 하거나 또는 여드름 흔적 완화, 피부 미백， 재생 촉진 또는 흥반 완화 등을 위하여 레이저를 시술하는 행위를 포함한다. 또한， 깊게 패이거나 변색된 흉터를 제거하거 나 완화시키기 위하여 레이저를 시술하는 경우를 포함하는 것이며, 상기 흉터는 구 체적으로 화상 또는 교통사고 등에 의해 얻어지는 것일 수 있으나 , 이에 제한되는 것'은 아니다。 The area of skin to be irradiated is not limited throughout the body, and specifically includes the face and the neck. Laser surgery refers to the acts performed for cosmetic or medical purposes. Specifically, laser treatment is performed to remove spots, blemishes, and spots, or laser treatment is performed to alleviate acne traces, to whiten skin, to promote regeneration, or to reduce fungus. In addition, deep L or intended to include the case of removing hageo treatment laser to mitigate or a discolored scar, the scar, but may be obtained by an image or a traffic accident to obtain the volume, will be limited to "is not.
<27> 본 명세서에서 피부를 '재생 '시킨다는 것은 레이저 시술한 피부에서 섬유 세 포의 활성을 유도 또는 촉진시키거나 섬유 세포를 레이저 시술 피부 부위로 이동시 킴에 따라， 피부를 재생시키거나 회복을 촉진시키거나 또는 새로운 피부의 생성을 촉진시키는 것을 의미한다.  In the present specification, 'regenerating' the skin induces or promotes the activity of the fiber cells in the laser-treated skin or moves the fiber cells to the laser-treated skin area, thereby regenerating the skin or promoting recovery. Or to promote the production of new skin.
<28> 본 발명의 조성물은 레이저로 인해 저하되었던 피부의 탄력을 증진시킬 수 있고 피부세포의 활성 및 이동을 촉진할 수 있으며， 피부 흥반을 개선할 수 있어 서, 피부의 회복， 구체적으로 레이저 시술 후 피부의 애프터 케어용으로 유용하게 사용할 수 있다. The composition of the present invention can enhance the elasticity of the skin which has been degraded by the laser, promote the activity and movement of skin cells, improve the skin uplift, recovery of the skin, specifically laser treatment It can be usefully used for aftercare of skin after.
<29> 본 발명의 일 관점인 조성물에 있어서， 상기 콜라겐 트리펩타이드는 Gly-X-Y  In the composition of the present invention, the collagen tripeptide is Gly-X-Y.
구조를 가질 수 있다. 상기 콜라겐 트리펩타이드는 글라이신 (Glycine, Gly)을 반드 시 포함하는 3개의 펩타이드 구조를 가질 수 있으며， 상기 X 또는 Y 위치에 올 수 있는 아미노산의 종류에는 제한이 없다。 구체적으로， 상기 아미노산은 글라이신， 알라닌, 발린， 류신, 이소류신， 트레오닌, 세린， 시스테인, 메티오닌， 아스파르트 산, 아스파라긴, 글루탐산， 글루타민， 리신, 아르기닌, 히스티딘, 페닐알라닌， 티 로신, 트립토판 또는 프롤린을 포함한다. 본 발명의 일실시예에서 X는 프를린일 수 있다ᅳ 본 발명의 일실시예에서 Y는 히드록시프롤린일 수 있다. 본 발명의 일실시예 에서 상기 콜라겐 트리펩타이드는 Gly-Pn)-Hyp의 트리펩타이드 서열일 수 있다. 이 경우, Gly-Pro-Hyp의 트리펩타이드는 전체 콜라겐 트리펩타이드 중 2.4~3.6 중량 % 일 수 있다. 또한， Gly-Pro— Hyp의 트리펩타이드는 전체 콜라겐 트리펩타이드 중 약 3 중량 %일 수 있다. It may have a structure. The collagen tripeptide may have three peptide structures that include glycine (Glycine, Gly), and there is no limitation on the type of amino acid that may come in the X or Y position. Specifically, the amino acid is glycine, Alanine, valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, phenylalanine, thi Leucine, tryptophan or proline. In one embodiment of the invention X may be proline. In one embodiment of the invention Y may be hydroxyproline. In one embodiment of the present invention, the collagen tripeptide may be a tripeptide sequence of Gly-Pn) -Hyp. In this case, the tripeptides of Gly-Pro-Hyp may be 2.4 to 3.6% by weight of the total collagen tripeptides. In addition, the tripeptides of Gly-Pro—Hyp may be about 3% by weight of the total collagen tripeptides.
<30> 상기 레이저 시술 후 피부의 재생 촉진용 조성물은 콜라겐 트리펩타이드를 전체 콜라겐 펩타이드 중 15 중량 % 이상 내지 90 중량 ¾ 이하로 포함할 수 있다 . 15 중량 ¾ 미만으로 콜라겐 트리펩타이드를 포함하면， 상처의 회복이 더디게 진행되고， 90 중량？ &를 초과하여 콜라겐 트리펩타이드를 포함하면， 다른 성분의 함량이 작아지 게 된다. 상기와 같은 관점에서 상기 상처 회복용 조성물은 콜라겐 트리펩타이드를 전체 콜라겐 펩타이드 중 20 중량 % 이상 내지 85 중량 % 이하， 25 중량 % 이상 내지 80 중량 ¾ 이하， 30 중량 % 이상 내지 75 중량 % 이하, 35 중량 % 이상 내지 70 중량 % 이하또는 40 중량 % 이상 내지 65 중량 ¾ 이하로 포함할 수 있다.  The composition for promoting skin regeneration after the laser treatment may include collagen tripeptide in an amount of 15 wt% or more to 90 wt% or less of the total collagen peptide. If the collagen tripeptide is included at less than 15 weight ¾, the healing of the wound proceeds slowly, and if the collagen tripeptide is included at more than 90 wt% &, the content of other components is reduced. In view of the above, the composition for wound repair may comprise at least 20 wt% to 85 wt%, at least 25 wt% to 80 wt% or less, at least 30 wt% to 75 wt%, of the collagen tripeptide in the total collagen peptide, 35 Or more than 70% by weight or less than 40% by weight or more and 65% by weight or less.
<31> 본 발명의 일 관점인 조성물에 있어서， 상기 콜라겐 펩타이드는 조성물 총 중량에 대하여， 1~80 중량 %로 함유될 수 있다. 콜라겐 펩타이드의 함량이 1 중량 % 미만이면 원하는 효과를 얻기 어렵고, 80 중량 ¾>를 초과하면 제형화에 어려움이 있 다。 상기와 같은 관점에서, 본 발명의 콜라겐 펩타이드는 조성물 총 중량에 대하 여 , 1~80 중량 %， 3-78 중량 %, 5~76 중량 ¾， 7~74 중량 ¾, 9~72 중량 %， 11-70 중량 %， 13-68 중량 %, 15-66 중량 17-64중량 %또는 19~62 중량 ¾로 함유될 수 있다.  In one aspect of the present invention, the collagen peptide may be contained in an amount of 1 to 80 wt% based on the total weight of the composition. If the content of the collagen peptide is less than 1% by weight, it is difficult to obtain the desired effect, and if it exceeds 80% by weight, it is difficult to formulate. In view of the above, the collagen peptide of the present invention is characterized by 1-80 weight%, 3-78 weight%, 5-76 weight ¾, 7-74 weight ¾, 9-72 weight%, 11-70 weight%, 13-68 weight%, 15-66 weight 17-64 weight % Or 19 to 62 weight ¾.
<32> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 피부 섬유세포의 이동 촉진용일 수 있다. 상기 섬유세포는 각질세포 또는 섬유아세포를 포함할 수 있으 나, 이에 제한되는 것은 아니다. 아울러， 상기 조성물은 피부 섬유세포를 이동시키 거나 또는 섬유세포의 이동을 더욱 촉진시킬 수 있다.  In a composition of one aspect of the present invention, the composition may be for promoting the movement of skin fiber cells. The fibrous cells may include keratinocytes or fibroblasts, but are not limited thereto. In addition, the composition may move the skin fiber cells or further promote the movement of the fiber cells.
<33> 본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 피부 섬유세포의 활성 촉진용일 수 있다. 상기 섬유세포는 각질세포 또는 섬유아세포를 포함할 수 있으 나, 이에 제한되는 것은 아니다. 아울러， 상기 조성물은 피부 섬유세포를 활성화시 키거나또는 섬유세포의 활성을 더욱 촉진시킬 수 있다.  In the composition of one aspect of the present invention, the composition may be for promoting the activity of skin fibroblasts. The fibrous cells may include keratinocytes or fibroblasts, but are not limited thereto. In addition, the composition may activate skin fibroblasts or further promote the activity of fibroblasts.
<34> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 피부 탄력 증가용일 수 있다. 상기 조성물은 피부의 탄력을 증진시켜서 늘어짐이 없는 피부를 만들 수 있고, 피부의 수분 감소를 최소화시켜주며， 유수분 밸런스를 맞춰줄 수 있다.  In a composition of one aspect of the present invention, the composition may be for increasing skin elasticity. The composition can improve the elasticity of the skin to create a sagging skin, to minimize the moisture loss of the skin, it can be adjusted to the oil and moisture balance.
<35> 본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 피부 흥반 감소용일 수 있다. 상기 조성물은 레이저로 인한 외부적인 자극에 피부가 붉어지는 흥반을 감소시킬 수 있다. <35> In the composition of one aspect of the present invention, the composition is for reducing skin plaque Can be. The composition can reduce the redness of the skin due to external irritation caused by the laser.
<36> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 비타민 C를 더 포함할 수 있다. 비타민 C를 더 포함할 경우 섬유아세포와 각질세포의 활성을 더욱 증가 시킬 수 있다.  In a composition of one aspect of the present invention, the composition may further include vitamin C. Including more vitamin C can further increase the activity of fibroblasts and keratinocytes.
<37> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 약학 조성물일 수 있 다.  In a composition of one aspect of the present invention, the composition may be a pharmaceutical composition.
<38> 본 발명에 따른 조성물을 의약품에 적용할 경우에는， 상기 조성물을 유효성 분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화할 수 있다.  When the composition according to the present invention is applied to a pharmaceutical product, the composition may be formulated as an oral or parenteral dosage form in solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier. Can be.
<39> 상기 경구 투여를 위한 제재로서는 정제， 환제, 과립제, 캡술제， 산제， 세립 제, 분제， 유탁제， 시럽제, 펠렛제 등을 들 수 있다. 또한， 상기 비경구 투여를 위 한 제재로는 주사제， 점적제， 연고, 로션， 스프레이, 현탁제， 유제， 좌제 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이 하게 제제화할 수 있으며 계면활성제, 부형제, 착색료， 향신료， 보존료， 안정제， 완층제, 현탁제， 기타상용하는 보조제를 적당히 사용할 수 있다.  Examples of preparations for oral administration include tablets, pills, granules, capsulants, powders, fine granules, powders, emulsions, syrups, pellets, and the like. In addition, the preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, loosening agents, suspending agents, and other commercially available auxiliaries can be suitably used.
<40> 본 발명에 따른 상기 약학 조성물은 경구， 비경구， 직장ᅵ 국소， 경피， 정맥 내， 근육 내， 복강 내， 피하 등으로 투여될 수 있다. <40> The pharmaceutical compositions according to the invention may be administered by oral, parenteral, rectal i topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous and the like.
<41> 또한， 상기 활성성분의 투여량은 치료 받을 대상의 연령， 성별, 체증과 치 료할 특정 질환 또는 병리 상태， 질환 또는 병리 상태의 심각도， 투여경로 및 처방 자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 일반적인 투여량은 0.001 mg/kg/일 내지 2000 mg/kg/일， 보다 구 체적으로는 0.5 mg/kg/일 내지 1500 mg/kg/일이다. 본 발명의 일 실시예에 있어서， 콜라겐 펩타이드의 경구 투여량은 0.005 g/kg/일 이상일 수 있고, 0.01 g/kg/일 이 상일 수 있고, 0.02 g/kg/일 이상일 수 있다. 본 발명의 일 실시예에 있어서， 콜라 겐 펩타이드의 경구 투여량은 0.5 g/kg/일 이하일 수 있고, 0.2 g/kg/일 이하일 수 있고， 0.1 g/kg/일 이하일 수 있다.  In addition, the dosage of the active ingredient will vary depending on the age, sex, weight of the subject to be treated and the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day. In one embodiment of the invention, the oral dosage of collagen peptide may be at least 0.005 g / kg / day, may be at least 0.01 g / kg / day, may be at least 0.02 g / kg / day. In one embodiment of the present invention, the oral dosage of collagen peptide may be 0.5 g / kg / day or less, 0.2 g / kg / day or less, and 0.1 g / kg / day or less.
<42> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 건강식품 조성물일 수 있다.  In a composition which is an aspect of the present invention, the composition may be a health food composition.
<43> 본 발명에 따른 조성물은 포함하는 다양한 형태의 식품 첨가제 또는 기능성 식품을 제공한다. 상기 조성물을 포함하는 발효유 치즈， 요구르트， 주스, 생균제 제， 정제， 과립제, 드링크제, 캐러멜， 다이어트바 등으로 제형화될 수 있고， 통상 적인 차 잎 형태나 티백 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. The composition according to the present invention provides various types of food additives or functional foods. Fermented milk cheese, yogurt, juice, probiotic, tablets, granules, drinks, caramel, diet bar, etc. containing the composition may be formulated, It can be processed into the form of tea leaves or tea bags and health supplements, and can be used in the form of various other food additives.
<44> 일 실시예에서 상기 조성물은， 본 발명이 목적으로 하는 주 효과를 손상시키 지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어， 물성 개선을 위하여 향료， 색소， 살균제， 산화방지제， 방부제, 보습제， 점증제 무기염류， 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도， 수용성 비타민， 유용성 비타민， 고분자 펩티드, 고분자 다당 및 해초 액기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며， 그 첨 가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01-5 중량 %, 보다 구체적으로는 0.01-3 중량 % 범위일 수 있다. In one embodiment, the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention. For example, it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickener inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties. In addition, it may further include auxiliary ingredients such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract. The components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention. For example, the added amount of the components may range from 0.01-5% by weight, more specifically 0.01-3% by weight, based on the total weight of the composition.
<45> 본 발명에 따른 조성물의 제형은 용액， 유화물, 점성형 흔합물, 타블렛， 분 말 둥의 다양한 형태일 수 있으며， 이는 단순 음용， 주사 투예 스프레이 방식 또 는 스퀴즈 방식 둥의 다양한 방법으로 투여될 수 있다. Formulations of the compositions according to the invention may be in various forms, such as solutions, emulsions, viscous mixtures, tablets, powders, which are administered by a variety of methods, such as simple drinking, injection spray or squeeze. Can be.
<46> 본 발명의 일 관점인 조성물에 있어서， 상기 조성물은 화장료 조성물일 수 있다.  In the composition which is one aspect of the present invention, the composition may be a cosmetic composition.
<47> 본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면， 용액， 수상에 유상을 분산시켜 얻은 에멀견 , 유상에 수상을 분산시켜 얻은 에멀견， 현탁액， 고체, 겔， 분말， 페이스트， 포말 (foam) 또는 에어 로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통 상적인 방법에 따라 제조될 수 있다.  The cosmetic composition according to the present invention may be provided in any formulation suitable for topical application. For example, it can be provided in the form of emulsions obtained by dispersing the oil phase in solution, water phase, emulsions obtained by dispersing the water phase in oil phase, suspensions, solids, gels, powders, pastes, foams or aerosol compositions. have. Compositions of such formulations may be prepared according to conventional methods in the art.
<48> 본 발명에 따른 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서， 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다 . 또한 본 발명에 따른 화장료 조성물은 보습제， 에몰리언트제， 자 외선 흡수제 , 방부제， 살균제 , 산화 방지제， pH 조정제， 유기 및 무기 안료， 향료， 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배 합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량 %， 구체적으로 0,01 내지 3 중량 ¾일 수 있다.  The cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range of not impairing the main effect, preferably other synergistic effects. In addition, the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, an ultraviolet absorbent, a preservative, a fungicide, an antioxidant, a pH adjuster, an organic and an inorganic pigment, a perfume, a cooling agent or a limiting agent. The blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0.01 to 5% by weight, specifically 0,01 to 3% by weight based on the total weight of the composition May be ¾.
<49> 이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다, 이들 실시 예는 오로지 본 발명을 예시하기 위한 것으로， 본 발명의 범위가 이들 실시예에 의 해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있 어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to examples. These examples are only for illustrating the present invention, and the scope of the present invention is defined by these examples. It will be apparent to one of ordinary skill in the art that it is not to be interpreted as limiting.
<50> [제조예 1] 콜라겐 펩타이드의 준비 Preparation Example 1 Preparation of Collagen Peptides
<5i> 본 발명에서 활성성분으로 사용되는 콜라겐 펩타이드는 젤라이스사 (HATC,  <5i> The collagen peptide used as an active ingredient in the present invention is a gel rice company (HATC,
Jellice Co., JAPAN)에서 구입한 것으로서， Gly-X-Y 형태의 트리펩타이드 (tripeptide)를 15 중량 % 이상 함유한 복합물로서， 구체적으로는 Gly-Pr으 Hyp의 트 리펩타이드 서열 약 3중량 %를 포함하는 콜라겐 트리펩타이드이다.  Jellice Co., JAPAN), which contains 15% by weight or more of Gly-XY-type tripeptide, specifically about 3% by weight of Gly-Pr's tripeptide sequence Collagen tripeptide.
<52> [실험예 1] 콜라겐 펩타이드의 각질세포, 섬유아세포 활성 촉진 효과  Experimental Example 1 Effects of Collagen Peptides on the Keratinocyte and Fibroblast Activity
<53> 【표 1】  <53> [Table 1]
Figure imgf000010_0002
Figure imgf000010_0002
<54> 5. 6회 계대 배양된 섬유아세포 (NHDF) (한국세포주은행， CCD986sk, KCLB, 한 국)와 각질세포 (HaCaT)(Dr N.E. Fusenig .Deutsches Krebsforschungszentrum, 5. Fibroblasts (NHDF) (Korea Cell Line Bank, CCD986sk, KCLB, Korea) and keratinocytes (HaCaT) (Dr N.E. Fusenig.Deutsches Krebsforschungszentrum,
Heidelberg, 독일)를 24-웰 폴레이트의 각 웰당 1x10*개의 세포가 들어가도록 분주 하였다. 1일간 배양한 후 FBS를 포함하지 않는 DMEM배지에서 24시간 배양하였다ᅳ 그 후 실시예 1의 콜라겐 펩타이드를 1, 10， 100 βΕ/mi 넣었으며, 실시예 2는 콜라 겐 펩타이드 100
Figure imgf000010_0001
과 비타민 C 100 ug/ l 을 동시에 처리하였다. 대조군에는Heidelberg, Germany) was aliquoted into 1 × 10 * cells per well of 24-well folate. After culturing for 1 day, the cells were incubated for 24 hours in a DMEM medium containing no FBS. Then, collagen peptides of Example 1 were added 1, 10, 100 βΕ / mi, and Example 2 100 collagen peptides.
Figure imgf000010_0001
And vitamin C 100 ug / l was treated simultaneously. In the control group
PBS를 배지 볼륨의 1/1000로 처리하였다. PBS was treated with 1/1000 of the media volume.
<55> 2일 동안 배양한 후, 생리 식염수에 용해한 MTT [3-(4,5-dimethylthiazol-2- yl )-2 ,5-di henyl tetrazolium bromide; Sigma, USA] 용액 300 ≠ 씩을 각각의 well에 첨가하여 4시간 동안 배양하였다. 배양 후 배지를 제거하고 200 ^의 dimethyl sulfoxide(DMS0; Junsei, Japan)를 첨가하여 형성된 formazan 결정을 용 해시킨 후, 96-웰 폴레이트 상으로 옮겨서 ELISA 분석기 (Spectra MAX 250， Molecular Devices Co., USA)로 540nm에서 흡광도를 측정하였다. 각각의 실험은 3 회 반복 시행하였다. 상기 실험결과는 도 1에 나타내었다. 도 1을 참조하면， 콜라 겐 펩타이드는 농도의존적으로 세포의 활성을 촉진시키는 것을 확인할 수 있고 더 욱이ᅳ 콜라겐 펩타이드와 비타민 C를 동시에 처리함에 따라 세포의 활성이 더욱 증 가하는 것을 확인할 수 있었다.  After incubation for 2 days, MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-dihenyl tetrazolium bromide dissolved in physiological saline; Sigma, USA] 300 ≠ each solution was added to each well and incubated for 4 hours. After incubation, the medium was removed and the formazan crystals formed by the addition of 200 ^ dimethyl sulfoxide (DMS0; Junsei, Japan) were dissolved, and then transferred onto 96-well folate, followed by ELISA analyzer (Spectra MAX 250, Molecular Devices Co., USA) and absorbance at 540 nm. Each experiment was repeated three times. The experimental results are shown in FIG. Referring to FIG. 1, collagen peptides were found to promote cell activity in a concentration-dependent manner, and furthermore, cell collagen peptides and vitamin C were simultaneously treated to increase cell activity.
<56> [실험예 2] 콜라겐 펩타아드와세포 이동 촉진 효과 <57> 콜라겐 펩타이드의 섬유아세포의 이동 촉진 효과를 확인하기 위하여， 상기 실시예 1의 콜라겐 펩타이드를 FBS에 녹여 하기와 같은 실험을 수행하였다. Experimental Example 2 Collagen Peptide and Cell Migration Promoting Effect In order to confirm the effect of promoting the migration of fibroblasts of the collagen peptide, the collagen peptide of Example 1 was dissolved in FBS and the following experiment was performed.
<58> 상처 치유 이동 분석을 위해， 각질세포를 2 X 105 세포 /웰 의 밀도로 6 웰 플레이트에 접종하였다. 다음 날， 상기의 실시예 1의 콜라겐 펩타이드를 3， 30 iigl \ , 농도가 되도록 처리하였다. 12시간 후 컨플루언트 (confluent) 세포를 미세 피 펫 팁으로 스크래칭하고 PBS로 세척하였다. 0， 46시간 정치배양 후에 사진 촬영하 였다. 세포 이동은 현미경 (X 50) 하에서 촬영하여 관찰하였다. 상기 실험결과는 도 2에 나타내었다, 도 2를 참조하면, 콜라겐 펩타이드는 농도의존적으로 세포의 이동 을 촉진시키는 것을 확인할 수 있다. For wound healing migration assays, keratinocytes were seeded in 6 well plates at a density of 2 × 10 5 cells / well. The next day, the collagen peptide of Example 1 was treated with 3, 30 iigl \, concentration. After 12 hours confluent cells were scratched with a fine pipette tip and washed with PBS. 0, 46 hours after the political culture was photographed. Cell migration was observed by photographing under a microscope (X 50). The experimental results are shown in FIG. 2, referring to FIG. 2, it can be seen that the collagen peptide promotes cell migration in a concentration-dependent manner.
<59> [실험예 3] 레이저 시술 후, 콜라겐 펩타이드에 의한 재생 촉진 효과 (인공피 부) Experimental Example 3 After Laser Treatment, Collagen Peptides Promote Regeneration Effect (Artificial Skin)
<60> 콜라겐 펩타이드의 레이저로 시술 후의 재생 촉진 효과를 확인하기 위하여, 상기 실시예 1의 콜라겐 펩타이드로 하기와 같은 실험을 수행하였다.  In order to confirm the regeneration promoting effect after the procedure by the laser of the collagen peptide, the following experiment was performed with the collagen peptide of Example 1.
<6i> 인공피부 (The EpiDermFT Full Thickness Skin Model, MatTek)를 인공피부전 용 성장 배지에서 5일간 적웅시켰다. 그 후 인공피부에 C02 laser (eC02, Lutronic) 를 Tip Type 120， Energy 40mJ, Size 8mm, Density 150 spots /cm2 조건으로 처리한 후 실시예 1의 콜라겐 펩타이드를 DMEM/F12 media에 10， 100 ^g/ra^ 의 농도가 되도 톡 처리하였다. 대조군에는 PBS를 배지 볼륨의 1/1000 처리하였다. 그 후 0， 1, 4 일째 인공피부를 회수하여 H&E 스테이닝을 통하여 인공피부의 회복 양상을 관찰하 였다. 상기의 실험결과는 도 3에 나타내었다. 도 3을 참조하면， 콜라겐 펩타이드는 농도의존적으로 레이저로 인한 시술 후， 피부의 재생을 촉진하는 것을 확인할 수 있다. <6i> Artificial skin (The EpiDermFT Full Thickness Skin Model, MatTek) was decanted in growth medium for artificial skin. Subsequently, the artificial skin was treated with C0 2 laser (eC0 2 , Lutronic) under Tip Type 120, Energy 40mJ, Size 8mm, Density 150 spots / cm 2, and the collagen peptide of Example 1 was applied to DMEM / F12 media. Tok treatment was carried out to a concentration of 100 ^ g / ra ^. The control group was treated with 1/1000 of the media volume of PBS. After that, artificial skin was recovered at 0, 1 and 4 days, and the recovery pattern of artificial skin was observed through H & E staining. The experimental results are shown in FIG. 3. Referring to FIG. 3, it can be seen that the collagen peptide promotes the regeneration of the skin after the procedure due to the laser concentration.
<62> [실험예 4] 콜라겐 펩타이드에 의한 재생 촉진 효과 (동물 실험)  Experimental Example 4 Regeneration-promoting Effect by Collagen Peptides (Animal Experiment)
<63> 콜라겐 펩타이드의 재생 촉진 효과를 확인하기 위하여， 무모생쥐 (hairless mice)를 동물모델로 선정하여 실험하였다. 6-7주령의 암컷 무모생쥐 (hair less mouse, SKH, HR-1)를 하기 표 2에 기재한 바와 같이 대조군， 실시예 2로 그룹 당 10 마리씩으로 나누어 실험기간동안사육하였다.  In order to confirm the regeneration promoting effect of the collagen peptide, hairless mice were selected as an animal model and tested. 6-7 week old female hairless mice (hair less mouse, SKH, HR-1) as a control group, as shown in Table 2 was divided into 10 animals per group in the experimental period was raised during the experiment.
<64> 【표 2】  <64> [Table 2]
Figure imgf000011_0001
<65> 대조군은 0.5ml의 생리식염수를 경구 투여하였고， 실시예 2는 콜라겐 펩타이 드를 고형분 기준으로 체중 (kg)당 600mg의 파우더를 0.5ml 식염수에 섞어 액체투여 용 주사기를 이용하여 경구 투여하였다. 투여기간은 총 4주로 동일한 시간에 투여 하였다. 경구 투여 후 2주차에 생쥐의 등에 펀치를 이용하여 창상올 형성했다. 그 후 2주 동안 생성된 창상의 면적을 측정하여 면적이 감소되는 경향을 관찰하였다. 상기의 실험결과는 도 4에 나타내었다. 도 4을 참조하면， 콜라겐 펩타이드는 창상 의 회복을 촉진하는 것을 확인할 수 있다.
Figure imgf000011_0001
In the control group, 0.5 ml of saline was orally administered, and in Example 2, collagen peptide was administered orally using a syringe for liquid administration by mixing 600 mg of powder per weight (kg) in 0.5 ml saline based on solid content. It was. The administration period was 4 weeks in total at the same time. Wounds were formed using punches on the back of mice two weeks after oral administration. Thereafter, the area of the wound produced during the two weeks was measured to observe the tendency of the area to decrease. The experimental results are shown in FIG. 4. Referring to Figure 4, it can be seen that collagen peptides promote the recovery of wounds.
<66> [실험예 5] 레이저 시술 후, 콜라겐 펩타이드에 의한 재생 촉진 효과 (임상실 험)  Experimental Example 5 After Laser Treatment, Collagen Peptides Promote Regeneration Effect (Clinical Experiment)
<67> 인체의 피부에서 콜라겐 펩타이드의 레이저로 인한 시술 후의 재생 촉진 효 과를 확인하기 위하여, 하기와 같은 임상실험올 '진행하였다. <67>, and the product was conducted clinical trials ol, such as to identify and promote regeneration after treatment due to the laser of the collagen peptide effect in the skin of the human body.
<68> 연령 40~49세의 성인여자 10명을 2군으로 나누고， 실험군은 콜라겐 펩타이드 를 1일 lg으로 하여 4주간 복용한 후 C02 프락셀 레이저를 얼굴 전체에 시술받았으 며， 시술 후 4주간 동일 용량의 콜라겐 펩타이드를 복용하였다. 대조군 (폴라시보 군)은 콜라겐 템타이드 대신 포도당 lg을 동일한 방법으로 복용하였다. 평가항목은 탄성도 (Cutometer), 경표피수분소실 (transepidermal water loss, TEffL) , 홍반지수 (Erythema index) , 환자의 주관적인 평가 (Patient global assessment)의 총 4가지 항목으로 평가하였다. 모든 관찰항목은 시술 일을 기준으로 4주전, 시술 전， 시술 직후, 시술 후 24시간 /48시간 /72시간 후, 2주 후， 4주 후에 총 8회에 걸쳐서 측정 하였다. 상기의 실험결과는 도 5 내지 도 8에 나타내었다. 도 5 내지 도 8을 참조하 면， 콜라겐 펩타이드는 피부의 탄력성을 증가시키고， 레이저 치료 후 흥반의 조기 감소효과를 보이는 것을 확인할 수 있다. <68> Ten adult women aged 40 to 49 years old were divided into two groups, and the experimental group received C0 2 Fraxel laser all over the face after taking 4 weeks of collagen peptide as lg per day. The same dose of collagen peptide was taken weekly. The control group (Polacibo group) took glucose lg instead of collagen temptide in the same way. The assessment items were assessed into four categories: elasticity (Cutometer), transepidermal water loss (TEffL), erythema index, and patient's subjective assessment. All observation items were measured 4 times before, 4 days after, 24 hours, 48 hours, 72 hours, 2 weeks, 4 weeks after the procedure. The experimental results are shown in FIGS. 5 to 8. 5 to 8, it can be seen that the collagen peptide increases the elasticity of the skin and shows an early reduction effect of pulp after laser treatment.
<69> [실험예 6] 콜라겐 펩타이드의 피부 수분 손실량 감소 효과 (임상실험)Experimental Example 6 Effects of Collagen Peptides on Skin Water Loss (Clinical Experiment)
<70> 콜라겐 펩타이드를 피부에 발랐을 시의 보습효과를 확인하기 위하여, 하기와 같은 임상실험을 진행하였다. In order to confirm the moisturizing effect when the collagen peptide was applied to the skin, the following clinical experiment was conducted.
<71> 아토피 피부염이나 알레르기성 질환 등 질환의 병력이 없는 건강한 성인 여 성 20명을 각각 2군으로 나누어 실험을 진행하였다. 실험군은 물에 용해시킨 lmg/ml의 콜라겐 펩타이드를 피부에 도포하였고, 대조군은 물을 피부에 도포하였 다. 도포 3시간 후, 피부의 수분 손실량 (TEWL)을 축정하였다 (도 9).  The experiment was carried out by dividing 20 healthy adult women without a history of atopic dermatitis or allergic diseases into two groups. The experimental group applied lmg / ml collagen peptide dissolved in water to the skin, and the control group applied water to the skin. After 3 hours of application, the water loss (TEWL) of the skin was accumulated (FIG. 9).
<72> 도 9를 참조하면， 콜라겐 펩타이드를 외용제로 이용하는 경우， TEWL 9, in the case of using the collagen peptide as an external preparation, TEWL
(Transepidermal water loss)이 감소하여 피부 보습에 도움을 줄 수 있음을 확인할 수 있다. [실험예 7] 경구용 콜라겐 펩타이드에 의한 재생 촉진 효과 (임상실험) 인체의 피부에서 경구용 저분자 콜라겐 펩타이드에 의한 레이저 시술 후의 피부 재생 촉진 효과를 확인하기 위하여, 하기와 같은 임상실험을 진행하였다. 연령 만 30~50세의 건강한 성인여성 8명 (평균 연령 37.25세)을 2군으로 나누 었고， 피험자의 선정에 있어서 안면부 피부 질환 (피부 감염， 습진, 건선， 주사， 포 진 등)이 있는 자, 전신적인 내복약이나 한약제를 복용하고 있는 사람， 다른 건강 기능식품을 복용하고 있는 사람， 심각한 전신질환을 동반한 환자 (암， 세균 및 바이 러스 감염 등), 심각한 정신질환자， 임산부， 기타 본 임상시험 수행이 곤란하다고 여겨지는 자는 제외하였다. 얼굴 전체에 프락셀 레이저 (fractional photothermolysis laser, Sellas )를 시술하는 여성 8명에 있어서, 실험군은 경구 용 저분자 콜라겐 펩타이드를 3g/day 양으로 하루에 한번씩， 시술 2주 전부터 시술 2주 후까지 총 4주， 28일간 복용하였고， 대조군은 경구용 저분자 콜라겐 펩타이드 를 복용하지 않고 총 4주간 임상실험에 임했다. 피험자는 레이저 시술일을 기준으 로 하여 시술 전 14일, 0일 (레이저 시술일)， 시술 후 1일， 3일， 7일， 14일 총 6회 내원하여 매 방문시 경표피수분소실량 (Transepi dermal water loss, TEWL), 피부 수 분도 (Corneometer), 흥반지수 (Erythema index), 색소지수 (Melanin index) , 불편사 항 등을 조사하고， 마지막 방문시에 피험자의 만족도도 조사하여， 레이저 시술 후 임상적 호전 및 부작용 여부에 대해 평가하였다. (Transepidermal water loss) can be reduced to help moisturize the skin. [Experiment 7] Regeneration promoting effect by oral collagen peptide (clinical experiment) In order to confirm the regeneration promoting effect after laser treatment by oral low molecular collagen peptide in the human skin, the following clinical experiments were conducted. Eight healthy women aged 30-50 years old (mean age 37.25 years old) were divided into two groups, and those with facial skin diseases (skin infections, eczema, psoriasis, injections, herpes, etc.) were selected. , People taking systemic oral or herbal medicine, people taking other dietary supplements, patients with serious systemic diseases (such as cancer, bacteria, and viral infections), people with severe mental illness, pregnant women, and other clinical trials Those who considered difficult to perform were excluded. In eight women who received fractional photothermolysis laser (Sellas) throughout the face, the experimental group used oral low molecular weight collagen peptides 3g / day once a day for a total of 4 weeks from 2 weeks to 2 weeks after the procedure. The group took 28 days, and the control group did not take oral low molecular collagen peptide for 4 weeks. Subjects visited the patient 6 times a day, 14 days, 0 days (laser procedure), 1 day, 3 days, 7 days, and 14 days after the laser procedure. dermal water loss (TEWL), skin moisture (Corneometer), Erythema index, pigment index (Melanin index), discomfort, etc. Postoperative clinical improvement and side effects were evaluated.
레이저 치료는 비침습적인 1550nm, 프락셀 레이저 (Sellas , Dinona사.， 서 울， 한국)를 사용하여 Stamp 모드를 적용하여 13 mJ/microthermal treatment zone Laser treatment was performed using a non-invasive 1550nm, Fraxel laser (Sellas, Dinona, Seoul, Korea) with a stamp mode of 13 mJ / microthermal treatment zone.
(MTZ)세기와 밀도 100 MTZ/cm2로 얼굴전체를 치료하였다. 모든 피험자는 임상시험 기간 중에 시험용 제품 외의 다른 의약품이나 건강기능식품의 사용은 제한하도록 하였다. 또한 임상시험 기간 중에 시험용 제품 이외는 별도의 피부에 대한 기능성 화장품， 처치 등은 하지 않도록 하였다. 임상 시험에 참여한 모든 피험자에게 동일 한 스킨， 로션을 제공하여 사용하게끔 하였다. 평가방법에 있어서， 수분평가는 Tewameter (Courage+Khazaka electronic The whole face was treated with (MTZ) intensity and density 100 MTZ / cm 2 . All subjects were advised to limit the use of other drugs or dietary supplements in addition to the product during the trial. In addition, during the clinical trial period, functional cosmetics and treatments on the skin other than the test product were not to be performed. All subjects who participated in the study were given the same skin and lotion. In the evaluation method, the moisture evaluation is Tewameter (Courage + Khazaka electronic
®  ®
GmbH, Cologne, Germany) , Corneometer (Courage+Khazaka electronic GmbH,  GmbH, Cologne, Germany), Corneometer (Courage + Khazaka electronic GmbH,
Cologne, Germany)를 사용하였고， 색소평가는 Mexameter (Courage+Khazaka electronic GmbH, Cologne, Germany)를 사용하여， 유효성 평가에 있어 1차 기준항 목 (Primary endpoint)으로 수분도를, 2차 기준항목 (Secondary endpoint)으로 색소 홍반지수를 측정하였다. Cologne, Germany), and the color evaluation was performed using the Mexameter (Courage + Khazaka electronic GmbH, Cologne, Germany), and the moisture content was used as the primary endpoint in the evaluation of efficacy, and the secondary criteria (Secondary). pigment as endpoint) The erythema index was measured.
<78> 홍반지수 (erythema index)는 대조군과 실험군 모두에서 시술 직후 크게 증가 하여 시술 1주일 후 정상으로 회복되는 양상을 보였다. 대조군에서는 시술 전과 비 교하였을 때 시술 직후 (P=0.007), 1일 후 (P=0.021), 3일 후 (P=0.006) 유의하게 증가하였다. 실험군에서는 시술 전과 비교하였을 때 시술 직후 (P=0.014), 1일 후 (P=0.032) 유의하게 증가하였으나， 시술 3일 후에는 유의한 차이를 보이지 않았다, 따라서 대조군에 비하여 실험군에서 시술 3일 후 흥반지수의 회복이 유의하게 더 빠른 것을 확인할 수 있으며， 실험결과는 도 10에 나타내었다.  The erythema index was significantly increased immediately after the treatment in both the control and experimental groups, and returned to normal after 1 week. In the control group, there was a significant increase immediately after the procedure (P = 0.007), after 1 day (P = 0.021), and after 3 days (P = 0.006). In the experimental group, significantly increased immediately after the procedure (P = 0.014) and after 1 day (P = 0.032) compared with the pretreatment, but there was no significant difference after 3 days. It can be seen that the recovery of the heungban index is significantly faster, the experimental results are shown in FIG.
<79> 색소지수 (melanin index)는 대조군과 실험군 모두에서 시술 직후 약간 감소 하였으나 시술 3일 후 기준치에 근접하게 회복하는 양상을 보였다. 이는 시술 직후 홍반지수가 크게 증가하면서 상대적으로 색소지수가 낮게 측정되었을 것으로 생각 이 된다. 대조군과 실험군 사이의 통계적으로 유의한 차이는 보이지 않았으며, 실 험결과는 도 11에 나타내었다.  The melanin index was slightly decreased immediately after the treatment in both the control and experimental groups, but returned to the baseline after 3 days. It is thought that the pigment index was relatively low as the erythema index increased immediately after the procedure. There was no statistically significant difference between the control group and the experimental group, and the experimental results are shown in FIG. 11.
<80> 경표피수분손실량 (TEWL)은 대조군과 실험군 모두에서 시술 직후 크게 증가하 여 시술 3일 후 감소하는 추세를 보이며 시술 1주일 후 정상으로 회복되는 양상을 보였다. 시술 3일 후와 시술 1주일 후에 대조군에 비하여 실험군에서 정상으로 회 복되는 정도가 더 큰 것으로 나타났으나， 통계적 유의성은 보이지 않으며， 실험결 과는 도 12에 나타내었다.  Hard epidermal moisture loss (TEWL) increased significantly immediately after the procedure in both the control and experimental groups, and decreased after 3 days, and returned to normal after 1 week. Three days after the procedure and one week after the procedure, the degree of recovery to the normal was greater in the experimental group than in the control group, but there was no statistical significance, and the experimental results are shown in FIG. 12.
<8i> 피부 수분도 (Corneometer)는 대조군과 실험군 모두에서 시술 직후 크게 감소 하였고, 시술 1일 후부터 회복하기 시작하여 시술 1주일 후 기준 수치까지 회복하 는 양상을 보였다. 대조군에서는 시술 전과 비교하였을 때 시술 직후 (PO.022), 3 일 후 (P=0.048) 유의하게 증가하였다. 실험군에서는 시술 전과 비교하였을 때 시 술 직후 (P-0.004), 1일 후 (P=0.042) 유의하게 증가하였으나， 시술 3일 후에는 유 의한 차이를 보이지 않았다. 따라서 대조군에 비하여 실험군에서 시술 3일 후 피부 수분도의 회복이 유의하게 더 빠른 것을 확인할 수 있으며， 실험결과는 도 13에 나 타내었다.  <8i> The skin moisture (Corneometer) was significantly decreased immediately after the treatment in both the control group and the experimental group, and began to recover from the first day after the procedure and then returned to the baseline value one week after the procedure. In the control group, there was a significant increase immediately after the procedure (PO.022) and after 3 days (P = 0.048). In the experimental group, significantly increased immediately after the procedure (P-0.004) and after 1 day (P = 0.042) compared with the pretreatment, but there was no significant difference after 3 days. Therefore, it was confirmed that the recovery of skin moisture was significantly faster after 3 days in the experimental group than the control group, and the experimental results are shown in FIG. 13.
<82> 환자의 만족도 (Patient satisfaction)는 불만족 (0-25%, 1점)， 약간 만족  Patient satisfaction is dissatisfaction (0-25%, 1 point), slightly satisfactory.
(25-50%, 2점)， 만족 (50~7¾, 3점), 매우 만족 (75~100%， 4점)으로 나누어 조사하였 고, 콜라겐 펩타이드를 복용한 실험군에서 3명 (75¾)， 복용하지 않은 대조군에서 2 명 (50%)이 2점 (만족， 50-75%)이상의 효과가 있다고 평가하였다. 또한 모든 환자에 서 레이저 시술에 따른 국소 부작용은 호소하지 않았고, 콜라겐 펩타이드의 경구 복용에 따른 소화기계 증상도 호소하지 않았다. 실험결과는 도 14에 나타내었다. <83> 결론적으로 경구용 펩타이드는 레이저 치료 후 홍반의 조기 감소효과와 피부 수화도의 조기 희복효과를 보임을 확인할 수 있으며， 주름개선 레이 저 시술 후 콜 라겐 팽타이드를 경구 복용하면 레이저 시술 후 수반되는 피부의 홍반과 건조감을 조기에 개선시킬 수 있다 . (25-50%, 2 points), Satisfaction (50 ~ 7¾, 3 points), Very Satisfaction (75 ~ 100%, 4 points), and 3 patients (75¾) in the experimental group taking collagen peptide. Two patients (50%) were evaluated as having more than two points (satisfaction, 50-75%) in the uncontrolled control group. In addition, all patients did not complain of local side effects from laser treatment and did not complain of gastrointestinal symptoms following oral administration of collagen peptides. The experimental results are shown in FIG. 14. In conclusion, oral peptides showed early reduction effect of erythema and early hydration effect of skin hydration after laser treatment. Oral administration of collagen pentide after wrinkle treatment laser treatment resulted after laser treatment. It can improve the erythema and dryness of the skin early.
<84> 이하 , 본 발명에 따른 조성물의 제형 예를 설명하나， 약학 조성물 및 화장료 조성물은 여 러 가지 제형으로 웅용 가능하며， 이는 본 발명을 한정하고자 함이 아 닌 단지 구체적으로 설명하고자 함이다 ,  Hereinafter, the formulation examples of the composition according to the present invention will be described, but the pharmaceutical composition and the cosmetic composition can be used in various formulations, which are intended to explain in detail only, not intended to limit the present invention.
<85> [제제예 1] 연질갑셀제  Preparation Example 1 Soft Chalcedel
<86> 제조예 1의 콜라겐 펩타이드 150 mg , 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시 틴 6 mg을 흔합하고， 통상의 방법에 따라 1 캡슐당 400 mg씩 층진하여 연질 캅셀을 제조하였다。  <86> 150 mg of collagen peptide of Preparation Example 1, palm oil 2 mg, palm hardened oil 8 mg, lead 4 mg and lecithin 6 mg were mixed and layered 400 mg per capsule according to a conventional method to prepare a soft capsule It was.
<87> [제제예 2] 정 제  <87> [Example 2] Purification
<88> 제조예 1의 콜라겐 펩타이드 150 mg, 포도당 100 mg, 홍삼추출물 50 mg, 전 분 96 mg 및 마그네슘 스테아레이트 4 mg을 흔합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후 , 60°C에서 건조하고 타정기를 이용하여 정제로 타정하였다. <88> Preparation Example 1 of the collagen peptide 150 mg, glucose 100 mg, ginseng extract 50 mg, Starch 96 mg, and magnesium and then by common combined addition of 30% ethanol, 40 mg stearate 4 mg form granules, 60 ° Dried at C and compressed into tablets using a tablet press.
<89> [제제예 3] 과립제  Preparation Example 3 Granules
<90> 제조예 1의 콜라겐 펩타이드 150 mg, 포도당 100 mg, 홍삼추출물 50 mg 및 전분 600 mg을 흔합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성 한 후， 60°C에 서 건조하여 과립을 형성 한 다음 포에 층진하였다 . 내용물의 최종 중량은 1 g으로 하였다 . <90> 150 mg of collagen peptide of Preparation Example 1, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C. Formed and stratified to the fabric. The final weight of the content was 1 g.
<91> [제제예 4] 드링크제  <91> [Example 4] Drinks
<92> 제조예 1의 콜라겐 펩타이드 150 mg , 포도당 10 흥삼추출물 50 mg , 구연 산 2 g 및 정제수 187.8 g을 흔합하고 병에 층진하였다 . 내용물의 최종 용량은 200 ml로 하였다.  150 mg of the collagen peptide of Preparation Example 1, 50 mg of glucose, 10 ginseng extract, 2 g of citric acid, and 187.8 g of purified water were mixed and layered in a bottle. The final dose of the contents was 200 ml.
<93> [제제예 5] 건강 식품의 제조  Preparation Example 5 Preparation of Health Food
<94> 【표 3】
Figure imgf000016_0001
<94> [Table 3]
Figure imgf000016_0001
상기의 비타민 및 미네랄 흔합물의 조성비는 비교적 건강식품에 적합한 성분 을 바람직한 실시예로 흔합 조성하였지만， 그 배합비를 임의로 변형 실시하여도 무 ¬방하며， 통상의 건강식품 제조방법에 따라 상기의 성분을 흔합한 다음, 과립을 제 조하고， 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다ᅳ  The composition ratio of the above-mentioned vitamin and mineral mixtures is a composition which is relatively suitable for health foods in a preferred embodiment, but the composition ratio may be arbitrarily modified. The granules can then be prepared and used to prepare health food compositions according to conventional methods.
[제제예 6] 건강 음료의 제조  Preparation Example 6 Preparation of Healthy Drinks
【표 4】 Table 4
Figure imgf000016_0002
Figure imgf000016_0002
<98> 통상의 건강음료 제조방법에 따라 상기의 성분을 흔합한 다음， 약 1시간 동  <98> After mixing the above ingredients in accordance with the usual health beverage manufacturing method, and for about 1 hour
안 85°C에서 교반 가열한 후， 만들어진 용액을 여과하여 멸균된 2£용기에 취득하 여 밀봉 멸균한 뒤 넁장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After stirring and heating at 85 ° C., the resulting solution was filtered, taken in a sterile 2 £ container, sealed, sterilized and stored at room temperature before use in the manufacture of a healthy beverage composition of the present invention.
<99> 상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 흔합 조성하였지만 수요계층이나, 수요국가， 사용 용도 등 지역적， 민족적 기호도에 따 라서 그 배합비율을 임의로 변형 실시하여도 무방하다. 본 발명이 속한 기술 분야 에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다 양한 웅용 및 변형을 행하는 것이 가능할 것이다. The composition ratio is a relatively preferred component suitable for a favorite beverage in a preferred embodiment Although it is established, the proportion may be arbitrarily modified according to regional and ethnic preferences such as demand class, demand country, and use purpose. Those of ordinary skill in the art to which the present invention pertains will be able to perform various uses and modifications within the scope of the present invention based on the above contents.
<ιοο> [제형예 1] 유연화장수 (스킨로션)  <ιοο> [Formulation example 1] supple cosmetic (skin lotion)
<ιοι> 【표 5】  <ιοι> 【Table 5】
Figure imgf000017_0001
Figure imgf000017_0001
[제형예 2] 영양화장수 (밀크로션)  Formulation Example 2 Nutritious Longevity (Milk Lotion)
【표 6】  Table 6
Figure imgf000017_0002
Figure imgf000017_0002
[제형예 3] 영양크림  Formulation Example 3 Nutrition Cream
【표 7] Λ _ [Table 7] Λ _
lb
Figure imgf000018_0001
lb
Figure imgf000018_0001
<108> [제형 예 5] 팩  [108] [Formulation Example 5] Pack
<109> 【표 9】 <109> [Table 9]
Figure imgf000019_0001
Figure imgf000019_0001
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바， 당업계의 통 상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며， 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따 라서， 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 둥가물에 의하여 정 의된다고 할 것이다.  The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims

【청구의 범위】 【Scope of Claim】
【청구항 13 【Claim 13
콜라겐 펩타이드를 유효성분으로 포함하는 레이저 시술 후 피부의 재생 촉진 용 조성물로서 , . A composition for promoting skin regeneration after laser treatment containing collagen peptide as an active ingredient.
상기 콜라겐 펩타이드는 콜라겐 트리펩타이드를 전체 콜라겐 펩타이드 중 15 중량 % 이상 포함하는， 레이저 시술 후 피부의 재생 촉진용 조성물. The collagen peptide is a composition for promoting skin regeneration after laser treatment, comprising collagen tripeptides at least 15% by weight of the total collagen peptides.
ί청구항 2】 ίClaim 2】
제 1항에 있어서, 상기 콜라겐 트리펩타드는 Gly-X-Y 구조를 가지는， 레이저 시술 후 피부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to claim 1, wherein the collagen tripeptide has a Gly-X-Y structure.
【청구항 3】 【Claim 3】
제 1항에 있어서， 상기 콜라겐 펩타이드는 조성물 총 중량에 대하여， 1~80 중 량¾로 함유된， 레이저 시술 후 피부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to claim 1, wherein the collagen peptide is contained in an amount of 1 to 80% by weight based on the total weight of the composition.
【청구항 4] [Claim 4]
제 1항에 있어서, 상기 조성물은 피부 섬유세포의 이동 촉진용인, 레이저 시 술 후 피부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to claim 1, wherein the composition is used to promote the movement of skin fibrous cells.
【청구항 5】 【Claim 5】
제 1항에 있어서， 상기 조성물은 피부 섬유세포의 활성 촉진용인, 레이저 시 술 후 피부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to claim 1, wherein the composition is used to promote the activity of skin fibrous cells.
【청구항 6】 【Claim 6】
저 U항에 있어서， 상기 조성물은 피부 홍반 감소용인， 레이저 시술 후 피부의 재생 촉진용 조성물. According to item U, the composition is for reducing skin erythema, and is a composition for promoting skin regeneration after laser treatment.
【청구항 7】 【Claim 7】
제 1항에 있어서， 상기 조성물은 피부 탄력 증가용인， 레이저 시술 후 피부의 재생 촉진용 조성물. The composition of claim 1, wherein the composition is for increasing skin elasticity, and for promoting skin regeneration after laser treatment.
【청구항 8】 【Claim 8】
제 1항에 있어서, 상기 조성물은 비타민 C를 더 포함하는， 레이저 시술 후 피 부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to claim 1, wherein the composition further comprises vitamin C.
【청구항 9] [Claim 9]
제 1항 내지 제 8항 중 어느 한 항에 있어서， 상기 조성물은 약학 조성물인， 레이저 시술 후 피부의 재생 촉진용 조성물. The composition according to any one of claims 1 to 8, wherein the composition is a pharmaceutical composition.
【청구항 10] [Claim 10]
제 1항 내지 제 8항 중 어느 한 항에 있어서， 상기 조성물은 건강식품 조성물 인 레이저 시술 후 피부의 재생 촉진용 조성물. The method of any one of claims 1 to 8, wherein the composition is a health food composition. A composition for promoting skin regeneration after phosphorus laser treatment.
【청구항 11】 【Claim 11】
계 1항 내지 제 8항 중 어느 한 항에 있어서， 상기 조성물은 화장료 조성물인， 레이저 시술 후 피부의 재생 촉진용 조성물. The composition according to any one of claims 1 to 8, wherein the composition is a cosmetic composition.
【청구항 12] [Claim 12]
제 1항 내지 제 8항 중 어느 한 항에 있어서， 상기 조성물은 경구 투여용인, 레이저 시술 후 피부의 재생 촉진용 조성물. The composition for promoting skin regeneration after laser treatment according to any one of claims 1 to 8, wherein the composition is for oral administration.
【청구항 13】 【Claim 13】
제 12항에 있어서， In clause 12,
상기 콜라겐 펩타이드의 투여양은 0.005 g/kg/일 내지 0.5g/kg/일인， 레이저 시술 후 피부의 재생 촉진용 조성물. A composition for promoting skin regeneration after laser treatment, wherein the administered amount of the collagen peptide is 0.005 g/kg/day to 0.5 g /kg/day.
PCT/KR2013/003744 2012-04-30 2013-04-30 Composition for accelerating regeneration after laser surgery WO2013165159A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20120045338 2012-04-30
KR10-2012-0045338 2012-04-30
KR10-2013-0047359 2013-04-29
KR1020130047359A KR102064469B1 (en) 2012-04-30 2013-04-29 Composition for promoting regeneration skin by laser

Publications (1)

Publication Number Publication Date
WO2013165159A1 true WO2013165159A1 (en) 2013-11-07

Family

ID=49514514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/003744 WO2013165159A1 (en) 2012-04-30 2013-04-30 Composition for accelerating regeneration after laser surgery

Country Status (1)

Country Link
WO (1) WO2013165159A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100025500A (en) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 Composition for improving beauty of skin containing collagen peptide
KR20110055126A (en) * 2009-11-19 2011-05-25 강원대학교산학협력단 The preparing method of starfish nanoparticle using pectin, and the product
KR101055153B1 (en) * 2008-10-15 2011-08-08 (주)더페이스샵 A anti-aging cosmetic Composition containing Hydrolysis Collagen Peptide stabilized in nano-liposome and Vitamin C

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100025500A (en) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 Composition for improving beauty of skin containing collagen peptide
KR101055153B1 (en) * 2008-10-15 2011-08-08 (주)더페이스샵 A anti-aging cosmetic Composition containing Hydrolysis Collagen Peptide stabilized in nano-liposome and Vitamin C
KR20110055126A (en) * 2009-11-19 2011-05-25 강원대학교산학협력단 The preparing method of starfish nanoparticle using pectin, and the product

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OKAWA ET AL.: "Oral administration of collagen tripeptide improves dryness and pruritus in the acetone-induced dry skin model", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 66, no. 2, 19 February 2012 (2012-02-19), pages 136 - 143 *
WATANABE-KAMIYAMA ET AL.: "Absorption and effectiveness of orally administered low molecular weight collagen hydrolysate in rats", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 58, no. 2, 2010, pages 835 - 841 *

Similar Documents

Publication Publication Date Title
KR100952109B1 (en) Personal care compositions comprising a dipeptide
US20110160137A1 (en) Composition containing collagen peptide for improving skin care
JP4252460B2 (en) Skin preparation for external use
JP2008105983A (en) Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink
WO2021005941A1 (en) Albizia julibrissin extract-containing composition
CN109394557B (en) Compositions for wrinkle improvement or elasticity enhancement of skin comprising sinapic acid
KR100837879B1 (en) Cosmetic Composition Containing Collagen from Deer Extracts and Process for Preparation Thereof
KR101305274B1 (en) Composition for improving collagen synthesis
JP2008105984A (en) Collagen production promoter, skin care preparation for external use, bathing agent, and food and drink
KR101218898B1 (en) Composition for improving collagen synthesis
KR102064469B1 (en) Composition for promoting regeneration skin by laser
JP3895636B2 (en) Anti-aging agent and external preparation for skin using the same
WO2013165159A1 (en) Composition for accelerating regeneration after laser surgery
KR20180108132A (en) Cosmetic composition for skin wrinkle improvement and prevention
AU2006264701A1 (en) Composition for dermatological treatment
CN117598924B (en) Plant polypeptide composition and application thereof
KR20160017891A (en) Composition for protecting skin with antioxidant activity comprising egf and placenta
KR102657626B1 (en) Composition for skin improvement containing collagen peptides derived from vegetable
KR20180108253A (en) Composition for skin improvement containing liquiritin apioside
KR102675965B1 (en) Composition for improving skin blood circulation
KR20180108255A (en) Composition for skin improvement containing parishin B
KR20180108254A (en) Composition for skin improvement containing parishin A
KR20180108251A (en) Composition for skin improvement containing ligustroflavone
KR101956842B1 (en) Cosmetic composition for anti-wrinkle and improving collagen synthesis comprising HCURE-1
KR100364289B1 (en) Skin care composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785088

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 17/04/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13785088

Country of ref document: EP

Kind code of ref document: A1